Close Menu

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for a point-of-care SARS-CoV-2 antibody test developed by Nirmidas Biotech.

The MidaSpot COVID-19 Antibody Combo Detection Kit is a single-use, lateral flow immunoassay designed for the qualitative detection and differentiation of immunoglobulin M and G against SARS-CoV-2 in serum or plasma. It is also authorized for use with fingerstick whole-blood samples in a point-of-care setting.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.